- Home
- RIG vs DFTX Comparison
RIG vs DFTX Comparison
Compare RIG & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | RIG | DFTX |
|---|---|---|
| Founded | 1926 | N/A |
| Country | Switzerland | United States |
| Employees | 5600 | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 5.9B |
| IPO Year | 2008 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RIG | DFTX |
|---|---|---|
| Price | $5.92 | $44.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $7.10 | ★ $38.50 |
| AVG Volume (30 Days) | ★ 45.8M | 2.1M |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $2,973,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $28.62 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.93 | $14.62 |
| 52 Week High | $7.66 | $49.70 |
Technical Indicators
Market Signals| Indicator | RIG | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 64.25 | 55.05 |
| Support Level | $5.95 | $40.46 |
| Resistance Level | $7.03 | $45.42 |
| Average True Range (ATR) | 0.22 | 2.76 |
| MACD | 0.06 | -0.07 |
| Stochastic Oscillator | 82.72 | 49.56 |
Price Performance
Historical ComparisonAbout RIG Transocean Ltd (Switzerland)
Transocean Ltd. is an international provider of offshore contract drilling services for oil and gas wells. The company provides mobile offshore drilling rigs, related equipment, and crews to support the drilling of oil and gas wells. Its fleet mainly consists of offshore rigs, including drillships, semisubmersibles, and jackups.
About DFTX Definium Therapeutics Inc. Common Shares
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.